Joshua Loh

THE IMPACT OF PERMANENT PACEMAKER IMPLANTATION FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT ON OUTCOME

Timing, causality, and outcomes of permanent pacemaker (PPM) following transcatheter aortic valve replacement (TAVR) remains poorly described.nnSymptomatic aortic stenosis patients undergoing TVAR were followed for timing and underlying causes of PPM implantation. They were categorized into 3 groups

DOES MILD AORTIC REGURGITATION IN PATIENTS POST-TRANSCATHETER AORTIC VALVE REPLACEMENT IMPACT MORTALITY?

Aortic regurgitation (AR) post-transcatheter aortic valve replacement (TAVR) is associated with increased mortality risk. The association between mild AR degree and outcome is not established.nnAll patients who underwent TAVR (n=407) were grouped by their post-TAVR AR degree [none (n=85); mild (n=

DOES PRIOR CORONARY ARTERY BYPASS GRAFTING SURGERY IMPACT OUTCOME IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT

Re-operation for aortic valve replacement after prior coronary artery bypass grafting surgery (CABG) is associated with increased risk for poor outcome. With transcatheter aortic valve replacement (TAVR) as an alternative for aortic valve surgery, it is not clear if prior CABG is also associated

CLINICAL IMPACT OF SECOND-GENERATION EVEROLIMUS-ELUTING STENTS COMPARED WITH FIRST-GENERATION DRUG-ELUTING STENTS IN DIABETIC PATIENTS UNDERGOING MULTIVESSEL PERCUTANEOUS CORONARY INTERVENTION

OBJECTIVESnThis study aimed to evaluate the safety and efficacy of everolimus-eluting stent (EES) use compared with first-generation drug-eluting stent (DES) use in diabetic patients undergoing multivessel percutaneous coronary intervention (PCI).nnnBACKGROUNDnAlthough the benefits of EES over first-generation DES were demonstrated for the general population, there is a paucity of data in diabetic patients with multivessel disease.nnnMETHODSnThe retrospective study cohort included 429 consecutive diabetic patients who underwent native multivessel PCI, defined as ≥2 same-generation DESs in ≥2 different native vessel territories during the index procedure. The primary safety endpoint was the combined incidence of death, non-fatal Q-wave myocardial infarction, and definite stent thrombosis (ST) at 1 year.nnnRESULTSnAt 1 year, the primary safety endpoint was reached in 2.9% of the patients in the EES group, which was significantly lower than the 9.3% noted with first-generation DES (P=.03). The occurrence of definite or probable ST was lower in the EES group (0% vs. 3.7%; P=.04). Similarly, there was a trend toward lower all-cause mortality (2.9% vs. 8.5%; P=.05) and cardiac death (1% vs. 4.9%; P=.08) in the EES group. However, there were no significant differences in the rates of target lesion revascularization (12.6% vs. 9.3%; P=.33) between groups. In a multivariate model, EES was independently associated with a lower risk of composite primary endpoint compared with first-generation DES (hazard ratio, 0.28; 95% confidence interval, 0.09-0.94).nnnCONCLUSIONnIn diabetic patients undergoing native multivessel PCI, the use of EES was associated with superior 1-year safety as compared with use of first-generation DES.

BLOOD TRANSFUSION INCREASES MORTALITY INDEPENDENT OF HEMOGLOBIN LEVELS IN ELDERLY PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT

Baseline anemia is associated with transfusions and increased risk of mortality in patients undergoing cardiac surgery and percutaneous coronary intervention. The impact of baseline anemia in patients undergoing transcatheter valve replacement (TAVR) remains unclear.nnOur cohort was divided into

CURRENT DEFINITIONS OF PERIPROCEDURAL MYOCARDIAL INFARCTION ARE NOT SURROGATE MARKERS FOR CATHETERIZATION LAB QUALITY OR CLINICAL TRIAL END POINTS

A consensus on what constitutes a clinically meaningful periprocedural myocardial infarction (PMI) remains debated. We evaluated the accuracy of two PMI definitions currently implemented for quality outcome assessment and clinical trial end points.nnPatients undergoing elective PCI with normal

CRT-145 Clinical Impact of Diabetes Mellitus on Long-term Clinical Outcomes in Patients Treated with Everolimus-Eluting Stent for Multivessel Percutaneous Coronary Intervention

Newer generation stents by means of more biocompatible components limiting inflammatory response have led to significant improvement in the cardiovascular outcomes.nnThe purpose of the present study is to evaluate the long term outcomes of diabetic patients undergoing multivessel PCI with the use of

CRT-710 Gender Differences in Clinical Presentation, and Outcomes of Patients Undergoing Balloon Aortic Valvuloplasty

Balloon aortic valvuloplasty (BAV) is being used more and more as a bridging procedure to more definitive surgery or TAVR. The present study aims at evaluating the gender differences in clinical characteristics and outcomes of patients undergoing BAV in TAVR era.nnFrom April 2009 to August 2012, the

SAFETY AND LONG–TERM OUTCOMES AFTER PCI IN HIV+ PATIENTS

HIV+ patients who undergo percutaneous coronary interventions (PCI) have been thought to be at high risk of adverse events. Data regarding the safety of PCI in HIV+ patients is sparse, with no data on long–term outcomes post–PCI.nnFrom April 2003 to September 2011, we compared baseline

OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION WHO UNDERGO TRANSCATHETER AORTIC VALVE REPLACEMENT

Atrial fibrillation (AF) is a poor prognostic factor for cardiac procedures and surgery. There are limited data regarding the correlation between baseline AF on patients with severe aortic stenosis who undergo transcathater aortic valeve replacement (TAVR). We sought to investigate the short– and